- Home
- PDX vs CLDX Comparison
PDX vs CLDX Comparison
Compare PDX & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDX
- CLDX
- Stock Information
- Founded
- PDX 2019
- CLDX N/A
- Country
- PDX NY
- CLDX United States
- Employees
- PDX N/A
- CLDX N/A
- Industry
- PDX Finance/Investors Services
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PDX Finance
- CLDX Health Care
- Exchange
- PDX Nasdaq
- CLDX Nasdaq
- Market Cap
- PDX 1.1B
- CLDX 1.2B
- IPO Year
- PDX N/A
- CLDX 2008
- Fundamental
- Price
- PDX $21.13
- CLDX $18.30
- Analyst Decision
- PDX
- CLDX Buy
- Analyst Count
- PDX 0
- CLDX 8
- Target Price
- PDX N/A
- CLDX $54.29
- AVG Volume (30 Days)
- PDX N/A
- CLDX 935.8K
- Earning Date
- PDX 01-01-0001
- CLDX 05-05-2025
- Dividend Yield
- PDX 4.95%
- CLDX N/A
- EPS Growth
- PDX N/A
- CLDX N/A
- EPS
- PDX N/A
- CLDX N/A
- Revenue
- PDX N/A
- CLDX $7,020,000.00
- Revenue This Year
- PDX N/A
- CLDX N/A
- Revenue Next Year
- PDX N/A
- CLDX N/A
- P/E Ratio
- PDX N/A
- CLDX N/A
- Revenue Growth
- PDX N/A
- CLDX 1.99
- 52 Week Low
- PDX $13.52
- CLDX $14.40
- 52 Week High
- PDX $21.05
- CLDX $47.00
- Technical
- Relative Strength Index (RSI)
- PDX 41.37
- CLDX 49.59
- Support Level
- PDX $20.32
- CLDX $17.45
- Resistance Level
- PDX $20.88
- CLDX $18.53
- Average True Range (ATR)
- PDX 1.23
- CLDX 1.37
- MACD
- PDX -0.12
- CLDX 0.29
- Stochastic Oscillator
- PDX 31.53
- CLDX 71.69
About PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited term, closed-end management investment company registered under the Investment Company. The fund's primary investment objective is to seek current income as a primary objective and capital appreciation as a secondary objective.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.